anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The promises of the cancer genome sequencing project, combined with various -omics technologies, have raised questions about the importance of cancer cytogenetic analyses. It is suggested that DNA sequencing provides high resolution, speed, and automation, potentially replacing cytogenetic testing. We disagree with this reductionist prediction. On the contrary, various sequencing projects have unexpectedly challenged gene theory and highlighted the importance of the genome or karyotype in organizing gene network interactions. Consequently, profiling the karyotype can be more meaningful than solely profiling gene mutations, especially in cancer where karyotype alterations mediate cellular macroevolution dominance. In this chapter, recent studies that illustrate the ultimate importance of karyotype in cancer genomics and evolution are briefly reviewed. In particular, the long-ignored non-clonal chromosome aberrations or NCCAs are linked to genome or chromosome instability, genome chaos is linked to genome reorganization under cellular crisis, and the two-phased cancer evolution reconciles the relationship between genome alteration-mediated punctuated macroevolution and gene mutation-mediated stepwise microevolution. By further synthesizing, the concept of karyotype coding is discussed in the context of information management. Altogether, we call for a new era of cancer cytogenetics and cytogenomics, where an array of technical frontiers can be explored further, which is crucial for both basic research and clinical implications in the cancer field.
Psychiatric comorbidity is common in cancer patients, emphasizing the need for comprehensive care. While depressive symptoms in pancreatic cancer have been studied, there is limited attention given to manic symptoms. This case report aims to contribute to the knowledge of pancreatic cancer psychiatric comorbidities by describing a case of a patient with stage IV pancreatic cancer who presented a sudden onset manic episode. The patient, a 61-year-old male with stage IV pancreatic cancer, presented at the Emergency Room with abrupt behavioural changes suggestive of a manic episode of 2 weeks of evolution. The patient had been undergoing chemotherapy and short 3-day cycles of corticosteroids for the past 9 months but had been off this treatment for 20 days when the episode began. Acute organic causes were ruled out. The patient was admitted to the psychiatric unit, where organic screening was expanded and treatment with antipsychotics and a mood stabiliser was initiated with subsequent remission of symptoms after 2 weeks. This case shows a manic episode as a rare psychiatric complication in pancreatic cancer. In the literature reviewed, four other similar cases have been observed. Further research is needed to elucidate the underlying pathophysiology and explore possible treatment strategies.
The AcuDoc trial is a single-center, prospective, triple masking, randomized, sham electroacupuncture-controlled study. A total of 50 adult patients with DOC and 25 healthy subjects will be enrolled in the study . Patients will be randomized into electroacupuncture (EA) group or sham EA group (1:1). All patients will receive EA or sham-EA treatment in the supine position at 9 am for 30 minutes once a day for consecutive 14 days and healthy subjects will receive no treatments. The primary objective is to determine the therapeutic benefit of electroacupuncture on the recovery of consciousness in patients with DOC after a 2-week intervention. Key secondary objective is to investigate the effect of electroacupuncture on the circuitry of consciousness using a multimodal approach integrating EEG, neuroimaging (rs-fMRI, amide proton transfer imaging, intravoxel incoherent motion imaging, neurite orientation dispersion and density imaging), and evoked potentials (SEP, BAEP). Other secondary outcomes include the effect of EA on the assessment of brain-computer interface after a 2-week intervention and on the Glasgow Outcome Scale-Extended score at 30 days and 90 days .
The invention discloses a traditional Chinese medicine for treating prolapse of lumbar intervertebral disc by using stylophorum lasiocarpum (Oliv.)fedde. The traditional Chinese medicine comprises the following raw material components in parts by weight: 13 to 17 parts of stylophorum lasiocarpum (Oliv.)fedde, 6 to 10 parts of salvia miltiorrhiza, 10 to 14 parts of ardisia villosa, 4 to 8 parts of madder, 6 to10 parts of cassia twig. 10 to 14 parts of centranthera grandiflora, 1 to 5 parts of barbed skullcap herb, 6 to 10 parts of Chinese angelica, 10 to 14 parts of eucommia ulmoides oliv, 4 to 8 parts of radix sileris, 1 to 5 parts of prepared common monkshood daughter root, 1 to 5 parts of liquorice, 13 to 17 parts of medicinal cyathula root, 13 to 17 parts of loofah sponge and 6 to 10 parts of barbed skullcap herb. The traditional Chinese medicine provided by the invention uses the blood-quickening stasis-dissipating function of the stylophorum lasiocarpum (Oliv.)fedde and used together with other Chinese medicines with effects of clearing and activating the channels and collaterals and relieving pain, combination rationality is achieved, and the traditional Chinese medicine has an excellent curing effect on patients suffering from prolapse of lumbar intervertebral disc, has high efficiency and is nontoxic or has no side effects.
The invention relates to a maca moisture mask with the oxidation-resistant effect and a preparation method. The maca moisture mask comprises konjac refined flour, a purple maca fresh root extract, a pyracantha fortuneana fruit extract, a ginkgo leaf extract, a white fungus extract and a luffa extract. According to the maca mask, the pure natural plant extracts are main components and can supplement rich oxidation-resistant factors for skin. The mask has the effects of delaying senescence and increasing skin elasticity, is soft in texture and good in skin attachment and can absorb and release a large number of nutritional ingredients. As known from mouse anti-aging experiments, the maca moisture mask can remarkably increase the content of hydroxyproline and superoxide dismutase and reduce the content of malondialdehyde and lipofuscin. By means of water retention and skin irritation experiments on skin of healthy females, it is known that the mask has good moisture retention, is free of irritation and has an ideal face beautifying effect, and anaphylaxis is not likely to happen.
The invention relates to a levetiracetam thin film coated tablet and a preparation method thereof. The mechanical compressibility of levetiracetam is poor. Starch slurry of which the mass concentration is 3-10% is added as a bonding agent, the use quantity of the starch slurry is 0.49-1.70% (mass percentage), and the tablet is prepared by wet granulation and tabletting. The problem that the tablet is difficult to make with few auxiliary ingredients in industrial production is solved, and a coating purpose is achieved. In the levetiracetam thin film coated tablet related to the invention, the mass percent content of the effective ingredient, levetiracetam, is 91.39-97.88%, and the auxiliary ingredients are relatively less. Six months of acceleration test shows that the levetiracetam thin film coated tablet cannot easily absorb moisture and has excellent dissolution stability. The starch slurry used as the bonding agent has great bonding property and is cheap and easy to obtain, and the production cost is lowered.
A system is disclosed for preventing the progression of type 2 diabetes and reducing blood sugar level to a normal range in a population of patients comprising a plurality of users diagnosed with diabetes or prediabetes. The system may include at least one administrator comprising a trained medical professional and a system server. Each user has a user interface in network communication with the server. Each user receives push communications on the user interface from the server comprising medical or lifestyle advice, and wherein each user receives prompts to enter data. A virtual coaching component may provide recommendations in real time to each user through their user interface on lifestyle choices designed to prevent the progression of diabetes. The server may aggregate results and determines trend and outcomes in the aggregate and provide data for the administrator to make decisions designed to prevent the progression of diabetes in the population of users.
OBJECTIVE: The aim of this study was to identify non-pharmacological pain relief therapies in children undergoing surgery.
DESIGN AND DATA SOURCES: Using keywords extracted from Medical Subject Headings and "Descriptores en Ciencias de la Salud" we searched for articles in the Web of Science, Scopus, Cuiden, PubMed, and CINHAL databases from the last five years, and performed a reverse search. We assessed the documentary quality of the articles using various standardized instruments.
RESULTS: The final review included eleven studies. In terms of cognitive-behavioral techniques, there is evidence that both music and video therapy are effective in reducing postoperative pain in children in seven studies, and therapeutic play in five studies. Other methods used less frequently but found to be effective included laughter therapy in one study and deep breathing in another. Regarding physical methods of pain relief, massage was found to be an effective non-pharmacological therapy for reducing pediatric postoperative pain in two studies and ineffective in another.
CONCLUSIONS: In this study, we highlight the importance of non-pharmacological therapies in pediatric postoperative pain management. Cognitive-behavioral techniques, especially music therapy, video therapy, and therapeutic play, reduce pediatric postoperative pain. They are therefore effective therapies that nurses can use in this area. Further research into the effectiveness of storytelling is necessary, as the evidence is not entirely conclusive. More evidence is also needed on physical methods of pain relief, particularly massage.
Oxidative stress and fibrosis may accelerate the progression of chronic kidney disease (CKD). DKK3 is related to regulating renal fibrosis and CKD. However, the molecular mechanism of DKK3 in regulating oxidative stress and fibrosis during CKD development has not been clarified, which deserves to be investigated. Human proximal tubule epithelial cells (HK-2 cells) were treated with H2O2 to establish a cell model of renal fibrosis. The mRNA and protein expressions were analyzed using qRT-PCR and western blot, respectively. Cell viability and apoptosis were evaluated using MTT assay and flow cytometry, respectively. ROS production was estimated using DCFH-DA. The interactions among TCF4, β-catenin and NOX4 were validated using luciferase activity assay, ChIP and Co-IP. Herein, our results revealed that DKK3 was highly expressed in HK-2 cells treated with H2O2. DKK3 depletion increased H2O2-treated HK-2 cell viability and reduced cell apoptosis, oxidative stress, and fibrosis. Mechanically, DKK3 promoted formation of the β-catenin/TCF4 complex, and activated NOX4 transcription. Upregulation of NOX4 or TCF4 weakened the inhibitory effect of DKK3 knockdown on oxidative stress and fibrosis in H2O2-stimulated HK-2 cells. All our results suggested that DKK3 accelerated oxidative stress and fibrosis through promoting β-catenin/TCF4 complex-mediated activation of NOX4 transcription, which could lead to novel molecules and therapeutic targets for CKD.
A device to output data associated a surgery may include a processor that may be configured to receive, before the surgery, first patient data. The processor may be configured to generate a transform before the surgery. The processor may be configured to receive second patient data during the surgery and to apply the transform based on the received second patient data satisfying a condition of the transform. The transform may be applied to the second patient data to derive third patient data. The third patient data may include the second information and contextual information about the second information. For example, the third patient data may include an alert to a health care professional with a present value of a biomarker and an indication of the magnitude and/or nature of the present value's deviation from a baseline.
BACKGROUND: Sarcopenia is characterized by the progressive loss of skeletal muscle mass, strength, and function, significantly impacting overall health and quality of life in older adults. This narrative review explores emerging targets and potential treatments for sarcopenia, aiming to provide a comprehensive overview of current and prospective interventions.
METHODS: The review synthesizes current literature on sarcopenia treatment, focusing on recent advancements in muscle regeneration, mitochondrial function, nutritional strategies, and the muscle-microbiome axis. Additionally, pharmacological and lifestyle interventions targeting anabolic resistance and neuromuscular junction integrity are discussed.
RESULTS: Resistance training and adequate protein intake remain the cornerstone of sarcopenia management. Emerging strategies include targeting muscle regeneration through myosatellite cell activation, signaling pathways, and chronic inflammation control. Gene editing, stem cell therapy, and microRNA modulation show promise in enhancing muscle repair. Addressing mitochondrial dysfunction through interventions aimed at improving biogenesis, ATP production, and reducing oxidative stress is also highlighted. Nutritional strategies such as leucine supplementation and anti-inflammatory nutrients, along with dietary modifications and probiotics targeting the muscle-microbiome interplay, are discussed as potential treatment options. Hydration and muscle-water balance are emphasized as critical in maintaining muscle health in older adults.
CONCLUSIONS: A combination of resistance training, nutrition, and emerging therapeutic interventions holds potential to significantly improve muscle function and overall health in the aging population. This review provides a detailed exploration of both established and novel approaches for the prevention and management of sarcopenia, highlighting the need for further research to optimize these strategies.
During sham sessions, tACS will be applied in the synchronous condition for 30 s of 2 mA normal-like stimulation at the beginning of each dual n-back task. After that, only a tiny current pulse (110 μA over 15 ms) for impedance control took place every 550 ms during the remaining time.
Current climate change brings with it a higher frequency of environmental stresses, which occur in combination rather than individually leading to massive crop losses worldwide. In addition to, for example, drought stress (low water availability), also flooding (excessive water) can threaten the plant, causing, among others, an energy crisis due to hypoxia, which is responded to by extensive transcriptional, metabolic and growth-related adaptations. While signalling during flooding is relatively well understood, at least in model plants, the molecular mechanisms of combinatorial flooding stress responses, for example, flooding simultaneously with salinity, temperature stress and heavy metal stress or sequentially with drought stress, remain elusive. This represents a significant gap in knowledge due to the fact that dually stressed plants often show unique responses at multiple levels not observed under single stress. In this review, we (i) consider possible effects of stress combinations from a theoretical point of view, (ii) summarize the current state of knowledge on signal transduction under single flooding stress, (iii) describe plant adaptation responses to flooding stress combined with four other abiotic stresses and (iv) propose molecular components of combinatorial flooding (hypoxia) stress adaptation based on their reported dual roles in multiple stresses. This way, more future emphasis may be placed on deciphering molecular mechanisms of combinatorial flooding stress adaptation, thereby potentially stimulating development of molecular tools to improve plant resilience towards multi-stress scenarios.
Systems, methods, and apparatus to dynamically manage interdependent, variable scheduled procedures are provided. An example method includes calculating a cumulative distribution function (CDF) for task(s) in a healthcare protocol based on a probability density function associated with task duration(s) for the task(s). The method includes determining a plurality of schedule risk states for each task in a healthcare protocol, each schedule risk state associated with an upper specification limit (USL) and a lower specification limit (LSL) along the CDF. The method includes identifying, within USL and LSL for each schedule risk state, setpoint(s) associated with probability(-ies) along the CDF. The method includes monitoring execution of task(s) in the healthcare protocol to identify a transition in schedule risk state according to USL and LSL. The method includes triggering an action to react to an actual or upcoming change in schedule risk state based on setpoint(s) associated with the schedule risk state.
Carcinogenicity studies have not been conducted with talazoparib.

Talazoparib was clastogenic in an in vitro chromosomal aberration assay in human peripheral blood lymphocytes and in an in vivo bone marrow micronucleus assay in rats. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of talazoparib, indicating the potential for genotoxicity in humans. Talazoparib was not mutagenic in a bacterial reverse mutation (Ames) test.

Fertility studies in animals have not been conducted with talazoparib. In repeat-dose toxicity studies up to 3-months duration, talazoparib-related findings in the testis and epididymis at doses ≥0.04 mg/kg/day in rats and ≥0.01 mg/kg/day in dogs included decreased organ weights, luminal cellular debris, reduced sperm, and degeneration/atrophy. These doses in rats and dogs resulted in approximately 1.0 times and 0.2 times, respectively, the exposure (AUC) in humans at the recommended dose of 1 mg daily. Follicular atresia of the ovary was observed in rats at doses ≥1 mg/kg/day talazoparib, approximately 9.5 times the AUC in patients at the recommended dose of 1 mg daily.
A composition for topical administration to an external body surface comprising: a polyhydroxy acid and a zinc salt of its conjugate base, wherein the polyhydroxy acid is selected from lactobionic acid, gluconolactone, a combination of lactobionic acid and gluconolactone and derivatives thereof; a partition coefficient enhancer selected from propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, 1,5-propane diol, propylene carbonate, dipropylene glycol, a glycol ether, diethylene glycol monoethyl ether, a pyrrolidone, N-methyl pyrrolidone and a combination thereof; a diffusion coefficient enhancer which is selected from a C12 to C14 straight chain fatty acid or a C14 straight chain primary alcohol and wherein the composition has a pH in the range of 2.7 to 5. The diffusion coefficient enhancer may be 1-tetradecanol. The zinc salt may be formed from zinc oxide. The composition may also comprise an emollient such as mineral oil, petrolatum, paraffin, hydrogenated polydecane, hydrogenated didecane, hydrogenated polyisobutene. The composition may also comprise a further acid, such as citric acid. The composition may also comprise a surfactant, which may be a surfactant system comprising methyl glucose sesquistearate and PEG-20 methyl glucose sesquistearate and optionally glyceryl stearate.
Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
Emtricitabine and tenofovir are principally eliminated by the kidney. Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of VIREAD [See Adverse Reactions (6.2)].

It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy and as clinically appropriate during therapy with TRUVADA. Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients at risk for renal impairment, including patients who have previously experienced renal events while receiving HEPSERA.

Dosing interval adjustment of TRUVADA and close monitoring of renal function are recommended in all patients with creatinine clearance 30–49 mL/min, [See Dosage and Administration (2.2)]. No safety or efficacy data are available in patients with renal impairment who received TRUVADA using these dosing guidelines, so the potential benefit of TRUVADA therapy should be assessed against the potential risk of renal toxicity. TRUVADA should not be administered to patients with creatinine clearance below 30 mL/min or patients requiring hemodialysis.

TRUVADA should be avoided with concurrent or recent use of a nephrotoxic agent.
A multiple dose Naloxone spray dosage form provides a container having two or more unit doses of Naloxone or a salt thereof in a liquid that is delivered by a metered dosage spray pump. In different embodiments, ten or more, 3-500, and 10-500 unit doses are provided in the container. The metered dosage spray pump delivers 50 to about 200 μL of Naloxone solution per spray, preferably, 100 μL per spray. Each unit dose contains about 0.5 mg to 12 mg of Naloxone or a pharmaceutically acceptable salt thereof, preferably, about 2 mg to 4 mg thereof in the delivered spray. A stable pharmaceutically acceptable composition of Naloxone is used in the multiple dose Naloxone spray dosage form. A method of treatment of opioid overdose involves administration of multiple doses using the multiple dose Naloxone spray dosage form.
The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to semaglutide 1.34mg/ml treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
Study team proposes to compare 2 standard doses of an anti-cancer drug called bevacizumab, 7.5mg/kg per dose vs. 15mg/kg per dose, given in combination with chemotherapy in patients with ovarian cancer that progressed on platinum chemotherapy. Higher doses in cases of antibody-based drugs like bevacizumab are not always better than lower doses, and in fact can cause more side effects without improving survival or shrinkage of cancer. Both 7.5 and 15mg/kg doses of bevacizumab every 3 weeks are used as standard protocol in BC Cancer for ovarian cancer patients, but only 15mg/kg doses are allowed for patients with ovarian cancer that progressed on platinum chemotherapy. This study is a pragmatic two-arm blinded study in which 70 patients with platinum-resistant ovarian cancer and eligible for bevacizumab + chemotherapy will be randomly assigned either to lower or higher standard dose of bevacizumab , combined with chemotherapy. Treating clinicians will decide how long the treatment will continue per standard of care. Duration of cancer control on CT scans, side effect profiles, and quality of life related to the two arms will be compared. If demonstrated, this finding will be practice-changing, with comparable efficacy and quality of life, potentially improved safety profile, as well as reduced provincial drug costs.